brain metastasis of various solid tumors
Conditions
Interventions
Case series:apatinib
Sponsors
The Second Affiliated Hospital of He'nan University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged over 18 years male and female; 2. The primary solid tumor was diagnosed by pathology, and the brain metastases were confirmed by imaging examination. The brain metastases have measurable lesions; 3. Received chemotherapy on a first-line or second-line basis; 4. ECOG 0-2; 5. Estimated survival time=3 mouths; 6. The damage caused by other treatments was recovered, in which the interval of nitrite or mitomycin was more than 6 weeks.Received other cytotoxic drugs, radiotherapy or surgery was more than 4 weeks, and the wound has been completely healed; 7. The main organ function is normal, and meet the following standards: (1) The standard of blood routine examination should be consistent: HB=90 g/L, ANC=1.5×10^9/L, PLT=80×10^9/L (2) Biochemical tests should meet the following criteria: BIL<1.25'ULN, ALT and AST<2.5'ULN; serum Cr or the clearance rate of endogenous creatinine is within the normal detection range of our hospital; 8. Patients voluntarily entered the study and signed informed consent form (ICF).
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. High blood pressure and failure to be reduced to normal range by antihypertensive drugs(Systolic pressure > 140 mmHg, diastolic pressure >90mmHg); 3. Variety of factors affecting oral drugs (such as inability to swallow, chronic diarrhea, and intestinal obstruction); 4. Coagulopathy (INR>1.5×ULN APTT>1.5×ULN), with Bleeding tendency or Undergoing acid dissolution or anticoagulant therapy; 5. Persons with a history of psychotropic substance abuse and who are unable to absolve or have mental disorders; 6. Participated in clinical trials of other drugs within four weeks; 7. Ascites with clinical symptoms requiring clinical intervention; 8. Received VEGFR inhibitors, such as bevacizumab, Solafinib, Sunitinib; 9. The researchers judged other situations that might affect the conduct and outcome of clinical studies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS; | — |
Countries
China
Contacts
Public ContactGuo Junhui
The Second Affiliated Hospital of He'nan University of Traditional Chinese Medicine
Outcome results
None listed